Abstract

Introduction: With the shift of research focus to personalized medicine in Alzheimer's Dementia (AD), there is an urgent need for tools that are capable of quantifying a patient's risk using diagnostic biomarkers. The Medical Informatics Platform (MIP) is a distributed e-infrastructure federating large amounts of data coupled with machine-learning (ML) algorithms and statistical models to define the biological signature of the disease. The present study assessed (i) the accuracy of two ML algorithms, i.e., supervised Gradient Boosting (GB) and semi-unsupervised 3C strategy (Categorize, Cluster, Classify—CCC) implemented in the MIP and (ii) their contribution over the standard diagnostic workup.Methods: We examined individuals coming from the MIP installed across 3 Italian memory clinics, including subjects with Normal Cognition (CN, n = 432), Mild Cognitive Impairment (MCI, n = 456), and AD (n = 451). The GB classifier was applied to best discriminate the three diagnostic classes in 1,339 subjects, and the CCC strategy was used to refine the classical disease categories. Four dementia experts provided their diagnostic confidence (DC) of MCI conversion on an independent cohort of 38 patients. DC was based on clinical, neuropsychological, CSF, and structural MRI information and again with addition of the outcome from the MIP tools.Results: The GB algorithm provided a classification accuracy of 85% in a nested 10-fold cross-validation for CN vs. MCI vs. AD discrimination. Accuracy increased to 95% in the holdout validation, with the omission of each Italian clinical cohort out in turn. CCC identified five homogeneous clusters of subjects and 36 biomarkers that represented the disease fingerprint. In the DC assessment, CCC defined six clusters in the MCI population used to train the algorithm and 29 biomarkers to improve patients staging. GB and CCC showed a significant impact, evaluated as +5.99% of increment on physicians' DC. The influence of MIP on DC was rated from “slight” to “significant” in 80% of the cases.Discussion: GB provided fair results in classification of CN, MCI, and AD. CCC identified homogeneous and promising classes of subjects via its semi-unsupervised approach. We measured the effect of the MIP on the physician's DC. Our results pave the way for the establishment of a new paradigm for ML discrimination of patients who will or will not convert to AD, a clinical priority for neurology.

Highlights

  • With the shift of research focus to personalized medicine in Alzheimer’s Dementia (AD), there is an urgent need for tools that are capable of quantifying a patient’s risk using diagnostic biomarkers

  • Our study was structured in two main parts: [1] a “group analysis” to assess the performances of two Medical Informatics Platform (MIP) ML algorithms to classify subjects in the dementia spectrum and to identify informative disease signatures and [2] a “single-case analysis” to measure the clinicians’ perceived impact of the MIP tools and test the change in their diagnostic confidence (DC) to identify Mild Cognitive Impairment (MCI) that could convert to AD within 2 years

  • Within the Cognitive Normal (CN) group, when quantified, 9% of subjects had abnormal AB1-42 cerebrospinal fluid (CSF) marker, and 82 and 97% of subjects had this abnormal marker in the MCI group and AD group, respectively

Read more

Summary

Introduction

With the shift of research focus to personalized medicine in Alzheimer’s Dementia (AD), there is an urgent need for tools that are capable of quantifying a patient’s risk using diagnostic biomarkers. Neuroscience seems locked in a symptom-based diagnostic paradigm moving forward without a wide-ranging biological classification scheme for brain diseases [7]. Holistic, multimodal, and multilevel analysis is required. This approach could optimize the effectiveness of disease prevention and treatment and minimize side effects by considering the specific makeup of genetic information, in vivo biomarkers (e.g., biological or imaging-derived), and phenotypic characterization to move toward the so-called personalized medicine

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.